Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H16Br2N2O2 |
Molecular Weight | 356.054 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
BrCCC(=O)N1CCN(CC1)C(=O)CCBr
InChI
InChIKey=NJBFOOCLYDNZJN-UHFFFAOYSA-N
InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2
DescriptionSources: http://activebiochem.com/drug/Pipobroman.htmlCurator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB00236
Sources: http://activebiochem.com/drug/Pipobroman.html
Curator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB00236
Pipobroman (trade names Vercite, Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. It is marketed by Abbott Laboratories. Pipobroman (PB) has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). The mechanism of action is uncertain but pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 Sources: http://www.drugbank.ca/drugs/DB00236 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VERCYTE Approved UsePipobroman Launch Date-1.25711999E11 |
|||
Primary | VERCYTE Approved UsePipobroman Launch Date-1.25711999E11 |
Doses
Dose | Population | Adverse events |
---|---|---|
75 mg 1 times / day multiple, oral Recommended Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, 61.8 n = 140 Health Status: unhealthy Condition: polycythemia vera Age Group: 61.8 Sex: M+F Population Size: 140 Sources: |
Disc. AE: Pancytopenia, Gastric pain... AEs leading to discontinuation/dose reduction: Pancytopenia Sources: Gastric pain Diarrhea Aplasia bone marrow |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Aplasia bone marrow | Disc. AE | 75 mg 1 times / day multiple, oral Recommended Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, 61.8 n = 140 Health Status: unhealthy Condition: polycythemia vera Age Group: 61.8 Sex: M+F Population Size: 140 Sources: |
Diarrhea | Disc. AE | 75 mg 1 times / day multiple, oral Recommended Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, 61.8 n = 140 Health Status: unhealthy Condition: polycythemia vera Age Group: 61.8 Sex: M+F Population Size: 140 Sources: |
Gastric pain | Disc. AE | 75 mg 1 times / day multiple, oral Recommended Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, 61.8 n = 140 Health Status: unhealthy Condition: polycythemia vera Age Group: 61.8 Sex: M+F Population Size: 140 Sources: |
Pancytopenia | Disc. AE | 75 mg 1 times / day multiple, oral Recommended Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, 61.8 n = 140 Health Status: unhealthy Condition: polycythemia vera Age Group: 61.8 Sex: M+F Population Size: 140 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Bone marrow aplasia after pipobroman: an immune-mediated mechanism? | 2001 Dec |
|
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. | 2002 Oct |
|
[Polycythemia vera]. | 2002 Oct 15 |
|
Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea. | 2003 |
|
Polycythemia vera. | 2003 Oct |
|
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. | 2003 Sep |
|
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. | 2004 Aug |
|
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. | 2005 Apr 1 |
|
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. | 2006 Jun |
|
Essential thrombocythemia. | 2007 Jan 8 |
|
A review of the therapeutic agents used in the management of polycythaemia vera. | 2007 Jun |
|
The treatment of polycythaemia vera: an update in the JAK2 era. | 2007 Mar |
|
Practical approach to treating essential thrombocythaemia: case studies. | 2007 Oct |
|
A case of bromoderma and bromism. | 2008 Feb |
|
Essential thrombocythemia: past and present. | 2009 Oct |
|
Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox. | 2010 Aug 18 |
|
Polycythemia vera. | 2010 Oct |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1590
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
||
|
WHO-ATC |
L01AX02
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
||
|
WHO-VATC |
QL01AX02
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
54-91-1
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
7271
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
CHEMBL1585
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
8347
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | RxNorm | ||
|
PIPOBROMAN
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
100000092245
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
2049
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
4842
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
3249
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
2192
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
DB00236
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
DTXSID7023485
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
C750
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
m8863
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB09875MIG
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
8242
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
D010885
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
6Q99RDT97R
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY | |||
|
25154
Created by
admin on Sat Dec 16 05:00:55 UTC 2023 , Edited by admin on Sat Dec 16 05:00:55 UTC 2023
|
PRIMARY |
ACTIVE MOIETY